A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy
收藏DataCite Commons2025-10-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00007566/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This phase 4, single-arm, open-label, multicenter study is designed to evaluate the efficacy
and safety of brentuximab vedotin as a single agent in adult participants with histologically
confirmed CD30+ relapsed or refractory classical Hodgkin Lymphoma who have not received a
prior stem cell transplantation (SCT) and are considered to be not suitable for SCT or
multiagent chemotherapy at the time of study entry.
提供机构：
Vivli
创建时间：
2021-12-22
